Nolvadex is the original brand name of tamoxifen, a selective estrogen receptor modulator (SERM). In men it blocks estrogen’s brake on the brain, so LH, FSH and testosterone rise: in 10 healthy men, two weeks of tamoxifen raised testosterone by about 40% and LH by about 70% (Birzniece 2010). That is why it is used for PCT after SARMs or steroids.

What has not been shown: no trial has tested tamoxifen as PCT after SARMs or steroids, and a 2026 review describes the evidence for post-cycle therapy in general as limited and mostly observational (Smit 2026). Its best-proven use in men is different: preventing breast growth caused by anti-androgen drugs (Boccardo 2005). Below: how it works, the doses studies used, what is known about using it after or during a SARM cycle, side effects and legal status.

What is Nolvadex?

Tamoxifen for Men – How Does Tamoxifen Work

Tamoxifen is a SERM: it binds estrogen receptors and blocks them in some tissues (breast, the hypothalamus) while acting more like estrogen in others. FDA first approved Nolvadex on 30 December 1977 (Drugs@FDA). The US label covers metastatic breast cancer in women and men, treatment after breast cancer surgery, DCIS, and lowering breast cancer risk in high-risk women (label). Use for gynecomastia, male infertility or after a cycle is off-label.

In men, three effects matter for PCT:

  • LH, FSH and testosterone go up. Testosterone +40% and LH +70% in healthy men (Birzniece 2010). In 94 subfertile men, tamoxifen 20 mg/day raised gonadotropins more than raloxifene (Tsourdi 2009).
  • SHBG goes up. SHBG rose about 20% in healthy men (Birzniece 2010). In men on bicalutamide, total testosterone rose but free testosterone did not change, because SHBG rose with it (Boccardo 2005).
  • IGF-1 goes down. About 25% lower after two weeks at 20 mg/day; raloxifene did not lower it (Birzniece 2010).

For how tamoxifen compares with the other options, see SARMs PCT and 13 things to know about SERMs.

Where Status
United States Prescription-only medicine. Approved for breast cancer treatment and risk reduction; other uses in men are off-label (label).
Germany Listed in the Anti-Doping Act annex: acquiring or possessing a “non-small quantity” for doping in sport is an offense (AntiDopG).
Sport (WADA) Prohibited at all times under S4.2, anti-estrogenic substances; a specified substance (WADA 2026).

For SARMs themselves, see are SARMs legal.

Nolvadex dosage: what studies used

No study has tested a tamoxifen dose for recovery after SARMs or steroids. These are the doses used in studies of men, and what happened:

Dose Who How long What happened
10 and 20 mg/day 10 healthy men 2 weeks each Testosterone up about 40%, LH up about 70%, SHBG up 20% and IGF-1 down 25% at the higher dose (Birzniece 2010)
20 mg/day 94 subfertile men Not stated in the abstract Gonadotropins rose, more than with raloxifene (Tsourdi 2009)
20 mg/day (with bicalutamide) 114 men with prostate cancer 48 weeks Breast growth in 10% vs 73% on placebo and 51% on anastrozole (Boccardo 2005)
1, 2.5, 5, 10 or 20 mg/day (with bicalutamide) 282 men with prostate cancer 12 months Breast events at 6 months fell from 86.2% (1 mg) to 8.8% (20 mg), vs 96.7% on placebo; hot flushes rose from 5 mg/day (Fradet 2007)

PCT guides online, including older versions of this page, describe 20–40 mg/day for about four weeks. That is anecdotal: no study has tested it.

How long it lasts. Tamoxifen has a half-life of about 5–7 days, and its main active metabolite, N-desmethyltamoxifen, about 14 days. Steady state takes about 4 weeks for tamoxifen and about 8 weeks for the metabolite (label). So a short course is still in the body weeks after the last capsule. The PCT & Bloodwork Planner shows clearance times side by side.

How Nolvadex is used after SARMs, and what the evidence says

People use tamoxifen after a SARM cycle to push LH and testosterone back up. The pieces of evidence that exist:

  • SARMs suppress, and recover. LGD-4033 lowered testosterone at 0.1–1 mg/day, and levels were back to baseline five weeks after stopping without treatment (Basaria 2013). Ostarine lowered total testosterone at 1–3 mg/day (Dalton 2011). See the evidence for each SARM.
  • Tamoxifen raises testosterone in men with a working hormone axis (Birzniece 2010). Whether that speeds recovery after SARMs has not been tested.
  • After steroids, the observational PCT data are mostly for clomiphene, not tamoxifen (İbis 2026), (Grant 2023).

Timing. No study defines when to start. A SERM taken while a SARM is still in the body works against a drug that is still suppressing. After five half-lives about 3% of a drug is left (StatPearls): roughly 5–8 days for LGD-4033 and 3–5 days for ostarine, based on their measured half-lives.

Checking. The way to see whether suppression is still there is a blood test after the SARM has cleared: total testosterone (fasting, in the morning), LH, FSH and SHBG. Because tamoxifen itself raises SHBG, free testosterone is useful too (Bhasin 2018). See SARMs bloodwork.

Can you take Nolvadex while on SARMs?

No study has tested tamoxifen together with a SARM. The closest data are from men taking the anti-androgen bicalutamide, where tamoxifen 20 mg/day taken alongside it for 48 weeks prevented most breast growth (Boccardo 2005). That is the evidence behind using it “on cycle” against gyno, but bicalutamide blocks the androgen receptor while SARMs activate it, so the results may not transfer. Older versions of this page advised never combining a SARM with PCT drugs and starting PCT only after the cycle; that advice was not based on a study either.

For breast growth on SARMs, see do SARMs cause gyno and the raloxifene guide.

Nolvadex vs Clomid vs enclomiphene

Tamoxifen (Nolvadex) Clomiphene (Clomid) Enclomiphene
Approved for Breast cancer (women and men) Ovulation problems in women Nothing
Male data Small hormone studies; strong trials for preventing drug-induced breast growth Meta-analysis of 19 studies in men with low testosterone (Huijben 2022); observational data after steroids Phase 2 and 3 trials in secondary hypogonadism (EMA 2018)
Half-life 5–7 days Zuclomiphene part builds up and lingers for weeks (label) 8–10 hours
Key risks Blood clots, stroke, liver changes, lower libido Visual symptoms, mood changes Blood clots, blurred vision
Fact sheet This page Clomiphene for men, Clomid PCT Enclomiphene for men

No trial has compared tamoxifen and clomiphene for recovery after SARMs or steroids.

Tamoxifen vs aromatase inhibitors for breast growth

Both are used against estrogen effects, but they did not perform the same. In men on bicalutamide, breast growth occurred in 10% on tamoxifen, 51% on anastrozole and 73% on placebo (Boccardo 2005). A 2025 meta-analysis of nine trials found tamoxifen cut the risk of breast growth and breast pain by about 82%, while anastrozole showed no significant benefit (Spagnolo 2025). Evidence for tamoxifen in teenage (pubertal) gynecomastia is weaker: six studies, none randomized (Lapid 2013). More on anastrozole: anastrozole for men.

Nolvadex side effects

Side effect What the evidence says Evidence
Blood clots (DVT, pulmonary embolism) and stroke More clotting events on tamoxifen. In the NSABP P-1 trial in women, pulmonary emboli occurred in 18 vs 6 on placebo. The boxed warning covers uterine cancer, stroke and pulmonary embolism in the risk-reduction setting (label). Trial
Loss of libido and impotence The label says these have led some male patients to stop tamoxifen (label). Trial
Hot flushes Rose at doses of 5 mg/day or more in men on bicalutamide (Fradet 2007). Trial
Liver changes Liver enzyme changes and, rarely, fatty liver, cholestasis, hepatitis and liver necrosis. The label advises periodic liver tests and blood counts (label). Trial
Eye changes Corneal changes, reduced color vision, retinal vein thrombosis, retinopathy and a borderline rise in cataracts (label). Trial
Overall tolerability in men Fewer than 5% of men stopped because of side effects; fewer side effects in men treated for infertility or gynecomastia than in men with cancer (Wibowo 2016). Observational

The clot and liver warnings are the ones most relevant to anyone with a history of blood clots or liver disease.

Nolvadex in drug tests

Tamoxifen is banned in sport at all times (WADA 2026). Anti-doping labs detect its metabolites in urine; six metabolites were found after a single 20 mg dose (Mazzarino 2010). No verified study defines a detection window. With a 5–7 day half-life and a 14-day metabolite, it stays in the body for weeks.

Where to buy Nolvadex

Tamoxifen is a prescription medicine in the US. Sarmguide’s current pick for research-grade tamoxifen is SwissChems Tamoxifen 20 mg, 60 capsules. SwissChems says each batch is tested by accredited third-party labs, mainly Janoshik Analytical, using HPLC, with a certificate of analysis (COA) per batch, and that a batch must test within 10% of the labeled amount (SwissChems FAQ page, checked 30 October 2026). It sells the product for laboratory research use only. Check that the COA you see matches your batch number.

Why we picked SwissChems: SwissChems review. Other PCT compounds: Buy PCT.

Bottom line

Tamoxifen reliably raises LH and testosterone in men and is the best-tested drug for preventing drug-induced breast growth. Its use as PCT after SARMs rests on that mechanism, not on a trial. It stays in the body for weeks and carries real risks, mainly blood clots, liver changes and sexual side effects in men. A blood test after the SARM has cleared is how suppression is measured.

Charts

Doses used in human studies of Tamoxifen What the published studies used and found. These are research doses reported in the studies, not recommendations. Dots mark each dose a study tested (per-kg doses are listed in the table only).
Doses used in human studies of Tamoxifen282 men (2007): 1–20 mg; 10 healthy men; randomi… (2010): 10–20 mg; 114 men (2005): 20 mg; 94 subfertile men (2009): 20 mg0 mg5 mg10 mg15 mg20 mg282 men (2007)282 men (2007): 1–20 mg1–20 mg10 healthy men; randomi… (2010)10 healthy men; randomi… (2010): 10–20 mg10–20 mg114 men (2005)114 men (2005): 20 mg20 mg94 subfertile men (2009)94 subfertile men (2009): 20 mg20 mg
Dose studiedWho took partDurationWhat the study foundSource
20 mg/day (with bicalutamide 150 mg/day)114 men with prostate cancer; randomized, double-blind vs placebo and vs anastrozole 1 mg/day48 weeksGynecomastia in 10% on tamoxifen vs 73% on placebo and 51% on anastrozole. Breast pain in 6% vs 39% and 27%. Adverse events were not increased with tamoxifen.PubMed 2005
1, 2.5, 5, 10 or 20 mg/day (with bicalutamide 150 mg/day)282 men with prostate cancer; randomized, placebo-controlled dose-response study12 monthsBreast events at 6 months: 86.2%, 60.0%, 55.3%, 23.5% and 8.8% on the five doses vs 96.7% on placebo. Hot flushes increased at doses of 5 mg or more.PubMed 2007
10 and 20 mg/day (crossover with raloxifene 60 and 120 mg/day)10 healthy men; randomized open-label crossover2 weeks per doseAt the higher dose, IGF-1 fell 25% and SHBG rose 20%. Testosterone rose about 40% and LH about 70%, more than with raloxifene.PubMed 2010
20 mg/day94 subfertile men with idiopathic oligozoospermia (part of a 284-man comparison with toremifene and raloxifene)Not stated in abstractGonadotropin levels rose significantly, more than with raloxifene.PubMed 2009

Sources: the studies linked in the table.

Embed this chart

Free to use with the credit link.

Half-life of Tamoxifen compared Elimination half-life in people, where measured (log scale; bars show the reported range). Values from different studies and routes are not directly comparable.
Half-life of Tamoxifen comparedTesamorelin: ~8–11 min; Ipamorelin: ~2 h; Enclomiphene: ~8–10 h; Clomiphene: ~5–24 h (No single value: enclomiphene part ~5–10 h; zuclomiphene part ~24 h with a very long tail (detectable for over a month)); Ostarine: ~14–24 h; LGD-4033: ~24–36 h (24–36 h); RAD-140: ~45 h; Anastrozole: ~2–2.1 days (~50 h); Tamoxifen: ~5–7 days (~5–7 days (tamoxifen); ~14 days (N-desmethyltamoxifen, main active metabolite)); CJC-1295: ~5.8–8.1 days (~6–8 days)6 min30 min1 h3 h6 h12 h1 day3 days1 weekTesamorelinTesamorelin: ~8–11 min~8–11 minIpamorelinIpamorelin: ~2 h~2 hEnclomipheneEnclomiphene: ~8–10 h~8–10 hClomipheneClomiphene: ~5–24 h (No single value: enclomiphene part ~5–10 h; zuclomiphene part ~24 h with a very long tail (detectable for over a month))~5–24 hOstarineOstarine: ~14–24 h~14–24 hLGD-4033LGD-4033: ~24–36 h (24–36 h)~24–36 hRAD-140RAD-140: ~45 h~45 hAnastrozoleAnastrozole: ~2–2.1 days (~50 h)~2–2.1 daysTamoxifenTamoxifen: ~5–7 days (~5–7 days (tamoxifen); ~14 days (N-desmethyltamoxifen, main active metabolite))~5–7 daysCJC-1295CJC-1295: ~5.8–8.1 days (~6–8 days)~5.8–8.1 days

Source: Sarmguide compound database; Tamoxifen value: Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan) (2026).

Embed this chart

Free to use with the credit link.

More on Tamoxifen

Frequently asked questions

What is Nolvadex?

Tamoxifen, a SERMEvidence: Law

Nolvadex is the original brand name of tamoxifen, a selective estrogen receptor modulator (SERM) approved by the FDA in 1977 for breast cancer in women and men. It is not a SARM.

Read the full section

How much Nolvadex do people take for PCT?

No dose tested for PCTEvidence: Trial

No study has tested a tamoxifen dose for recovery after SARMs or steroids. Studies in men used 10–20 mg/day, and the schedules in online PCT guides are anecdotal.

Read the full section

Can you take Nolvadex while on SARMs or only for PCT?

Never tested with a SARMEvidence: Trial

No study has tested tamoxifen together with a SARM. In men on the anti-androgen bicalutamide, 20 mg/day for 48 weeks prevented most breast growth (10% vs 73% on placebo), but bicalutamide blocks the androgen receptor while SARMs activate it.

Read the full section

Is Nolvadex enough for PCT?

Unknown; no trialEvidence: Trial

No trial answers it; tamoxifen raises LH and testosterone in men with a working hormone axis. In the one SARM trial that followed people after stopping (LGD-4033 at up to 1 mg/day for 21 days), hormones recovered within five weeks without treatment.

Read the full section

Nolvadex or Clomid for PCT?

Never comparedEvidence: Human data

No trial has compared them for recovery after SARMs or steroids, and the observational post-steroid data are mostly for clomiphene. Clomiphene carries a warning about visual symptoms; tamoxifen about blood clots and stroke.

Read the full section

How long does tamoxifen stay in your system?

Weeks; half-life 5–7 daysEvidence: Human data

Tamoxifen has a half-life of about 5–7 days and its main metabolite, N-desmethyltamoxifen, about 14 days. Steady state takes about 4 weeks for tamoxifen and 8 weeks for the metabolite.

Read the full section

What are the side effects of Nolvadex in men?

Clots, stroke, liver, libidoEvidence: Trial

The label warns about blood clots and stroke, reports liver enzyme and eye changes, and says loss of libido and impotence have led some men to stop. Hot flushes increased at 5 mg/day or more in one male trial.

Read the full section

Does tamoxifen raise testosterone?

Yes, in studies of menEvidence: Human data

In 10 healthy men, tamoxifen raised testosterone about 40% and LH about 70% over two weeks. It also raised SHBG about 20%, so free testosterone rises less than total testosterone.

Read the full section

Does tamoxifen lower IGF-1?

Yes, about 25%Evidence: Human data

In healthy men, 20 mg/day lowered IGF-1 by about 25% over two weeks. Raloxifene did not.

Read the full section

Is tamoxifen banned in sport?

Yes, banned by WADAEvidence: Law

WADA lists tamoxifen under S4.2 (anti-estrogenic substances), prohibited at all times.

Read the full section

Is SwissChems Nolvadex legit?

Seller says batches are testedEvidence: Limited

SwissChems sells tamoxifen 20 mg capsules for laboratory research use and says every batch is tested by accredited third-party labs, mainly Janoshik Analytical, using HPLC, with a 10% tolerance on the labeled amount. Check that the COA matches the batch number.

Read the full section

Sources

  1. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men 2010 · PMID 20843951
  2. Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives 2026 · PMID 42644333
  3. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 2005 · PMID 15681525
  4. Drugs@FDA: NOLVADEX, NDA 017970 1977
  5. Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan) 2026
  6. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia 2009 · PMID 18692782
  7. Anlage zum Anti-Doping-Gesetz (AntiDopG), BGBl. 2023 I Nr. 67 2023
  8. World Anti-Doping Code International Standard: Prohibited List 2026 2025
  9. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study 2007 · PMID 17270340
  10. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men 2013 · PMID 22459616
  11. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  12. Post-cycle therapy after short-term anabolic-androgenic steroid use: comparative outcomes in recreational bodybuilders 2026 · PMID 41147237
  13. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study 2023 · PMID 38102386
  14. Elimination Half-Life of Drugs (StatPearls, NCBI Bookshelf) 2025 · PMID 32119385
  15. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline 2018 · PMID 29562364
  16. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis 2022 · PMID 34933414
  17. EnCyzix (enclomifene): public assessment report, EMA/88321/2018 2018
  18. CLOMID (clomiphene citrate) tablets – prescribing information (DailyMed) 2025
  19. Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials 2025 · PMID 40244528
  20. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review 2013 · PMID 23729603
  21. Tamoxifen in men: a review of adverse events 2016 · PMID 27152880
  22. Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry 2010 · PMID 20187079